Mild to Moderate Alzheimer's Disease
Neurology
3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NovartisRivastigmine Patch
GenomicsORY-2001 Low dose
Clinical Trials (2)
Total enrollment: 142 patients across 2 trials
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
Start: May 2016Est. completion: May 2018118 patients
Phase 4Completed
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
Start: May 2019Est. completion: Nov 202024 patients
Phase 2Completed
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space